You seem to be using an outdated version of Internet Explorer. Please note that this site does not support this browser version (a href="http://windows.microsoft.com/de-de/windows/end-support-help">as does Microsoft). You may experience design inconsistencies and error messages. We are sorry for any inconveniences.

News

Scipio bioscience announces its seed funding

14. November 2017
Scipio bioscience, a Paris-based biotechnology company devoted to providing a novel sample preparation solution for single-cell studies in the form of benchtop kits, announces today the completion of its initial fundraising. A total of €1.2m has been obtained from two European seed funds: Paris, France-based Seventure Partners’ Quadrivium I seed fund and Bonn, Germany-based High-Tech Gründerfonds. These funds will fuel More …

Focus on Medical Device Regulation: BVMed, Earlybird, High-Tech Gründerfonds and BIOCOM publish “MedTech Radar 9”

13. November 2017
The EU Medical Device Regulation heralds a new era for the medical technology sector: in future, any company wishing to bring medical devices to market must face the requirements of this new regulatory framework. This implies a sizeable challenge for the many small and medium-sized enterprises in Germany. The 9th edition of the joint media service “MedTech Radar”, published by More …

The game changer in surgical education – breaking bones for better patient outcomes

10. October 2017
Cologne based MedTech start-up RIMASYS received financing from investor HTGF. The investment will be utilized to expand the fracture portfolio, upgrade production technology and increase international reach. RIMASYS is the worldwide sole manufacturer of life-like fractures in human specimen with intact soft tissue mantle. Enabling medical science to enhance surgical skills and the health care industry to develop better implants More …

OMEICOS Secures Extension of Series B Financing Round to Expand its Technology into Ophthalmology

4. October 2017
OMEICOS adds REMIGES Ventures as new investor and announces the incorporation of U.S. subsidiary OMEICOS Ophthalmics, Inc. OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases, today announced that it has secured an extension of its recently closed Series B financing round. The financing by US-based REMIGES Ventures will help More …

BORN2GROW supports biotech start-up Venneos with its further growth

26. September 2017
Venture capital fund BORN2GROW has invested in Stuttgart-based Venneos GmbH in the current round of series A financing. The start-up is successfully developing and marketing the CAN-Q – a silicon chip-based imaging system for analysing biological cells. “We are thrilled to have BORN2GROW on-board as a new investor, and that we will be able to benefit from its extensive expertise More …

Atriva reaches a development milestone and receives an additional tranche of running seed financing to develop its influenza therapeutic to clinical stage

21. September 2017
The next generation of Antiviral Therapies: Co-Led by Stichting Participatie Atriva and High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received a second tranche of its running seed financing in total of € 3 Mn from Dutch, German and Canadian investors, after lead compound ATR-002 (Atriva’s antiviral MEK-Inhibitor against Influenza) has passed an important preclinical milestone paving the way to clinical More …

Evonik is investing in NUMAFERM, a specialist in the biotechnological production of peptides

18. September 2017
NUMAFERM makes the production of peptides more efficient Investment strengthens Evonik’s growth engines Health & Care and Specialty Additives at Evonik New technical applications are becoming realistic for the first time Through its Venture Capital unit, Evonik has invested in the start-up NUMAFERM and now holds a minority share in the spin-off of Heinrich Heine University Düsseldorf. The investment was More …

Reactive Robotics GmbH is on track

8. September 2017
Clinical validation, market entry in Germany and further countries secured by second investment round with existing and new investors Founded in 2015 in Munich, Reactive Robotics GmbH is a medical device start-up with the corporate objective to provide the best possible Very Early Mobilization (VEM) to intensive care patients as early as 24 hours after hospital admission, directly in the More …

MSD to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology

6. September 2017
MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK)), and Rigontec today announced that MSD will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. Under the terms More …

AMAL Therapeutics raises €8 million (CHF 8.8 million) in first closing of Series B financing round

5. September 2017
 Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund Funds will be used to support: Clinical development of lead vaccine (ATP128) for colorectal cancer through to clinical proof-of-concept Further development of KISIMA technology platform for therapeutic tumour vaccination AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed More …